Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Pure autonomic failure may serve as a prodromal manifestation of Parkinson disease, Lewy body dementia, and multiple system atrophy.
Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
An experimental drug that Theravance Biopharma touted as a potential first-in-class medicine for multiple system atrophy has failed a Phase 3 study, triggering a corporate shakeup that ends this ...
Study coordinators who want to add a study should Submit a Clinical Trial. For more information or to remove a study, please email pa-webteam@bcm.edu. MyChart is a ...
Multiple system atrophy and Parkinson’s disease are progressive nervous system disorders that affect everyday movements. Multiple system atrophy is rarer and tends to progress more quickly. Multiple ...
Study coordinators who want to add a study should Submit a Clinical Trial. For more information or to remove a study, please email pa-webteam@bcm.edu. MyChart is a ...
An implanted device (typically used to treat pain) that stimulates the thoracic spinal cord and sympathetic ganglia was coupled with accelerometers that detect changes in body position. With this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results